XML 108 R84.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting (Details) - Schedule of Segment Information for the Reportable Segments - AUD ($)
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Disclosure of operating segments [line items]      
Hyper-immune products revenue $ 4,902,865 $ 1,804,705 $ 765,193
Cost of sales of goods (1,566,068) (495,558) (241,691)
Gross profit 3,336,797 1,309,147 523,502
Other income 3,408,199 2,591,498 957,725
Fair value gains/(losses)to financial assets (557,676) (523,666)
Net foreign exchange gains/(losses) (27,603) 363,724 247,558
Movement in inventory provision 430,932
General and administrative expenses (4,555,726) (4,220,905) (3,524,388)
Research and development expenses (5,375,461) (2,592,145) (657,715)
Selling and marketing expenses (2,029,648) (927,423) (416,537)
Operating profit/(loss) (5,801,118) (3,568,838) (2,869,855)
Finance income 327,756 116,323 21,785
Finance costs (7,576) (9,652) (6,184)
Share of loss from associates (1,456,019) (324,340)
Income tax expense
Profit/(loss) for the year (6,936,957) (3,786,507) (2,854,254)
Assets      
Segment assets 15,549,969 21,988,182 24,855,824
Total assets 15,549,969 21,988,182 24,855,824
Liabilities      
Segment liabilities 2,840,525 2,371,346 1,678,423
Total liabilities 2,840,525 2,371,346 1,678,423
Research and Development [Member]      
Disclosure of operating segments [line items]      
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income 3,364,439 2,551,813 933,140
Fair value gains/(losses)to financial assets  
Net foreign exchange gains/(losses)
Movement in inventory provision  
General and administrative expenses (460,251) (460,251)
Research and development expenses (5,375,461) (2,592,145) (657,715)
Selling and marketing expenses
Operating profit/(loss) (2,471,273) (500,583) 275,425
Finance income
Finance costs
Share of loss from associates  
Income tax expense  
Profit/(loss) for the year (2,471,273) (500,583) 275,425
Assets      
Segment assets 768,370 398,391 257,500
Total assets 768,370 398,391 257,500
Liabilities      
Segment liabilities 604,018 604,018 7,053
Total liabilities 604,018 604,018 7,053
Hyperimmune Products [Member]      
Disclosure of operating segments [line items]      
Hyper-immune products revenue 4,902,865 1,804,705 765,193
Cost of sales of goods (1,566,068) (495,558) (241,691)
Gross profit 3,336,797 1,309,147 523,502
Other income 43,760 39,685 24,585
Fair value gains/(losses)to financial assets  
Net foreign exchange gains/(losses)
Movement in inventory provision 430,932  
General and administrative expenses (3,565) 26,256 (164,087)
Research and development expenses
Selling and marketing expenses (2,029,648) (927,423) (416,537)
Operating profit/(loss) 1,347,344 878,597 (32,537)
Finance income
Finance costs
Share of loss from associates  
Income tax expense  
Profit/(loss) for the year 1,347,344 878,597 (32,537)
Assets      
Segment assets 2,845,096 2,078,643 1,688,910
Total assets 2,845,096 2,078,643 1,688,910
Liabilities      
Segment liabilities 206,524 206,524 150,151
Total liabilities 206,524 206,524 150,151
Corporate [Member]      
Disclosure of operating segments [line items]      
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income
Fair value gains/(losses)to financial assets (557,676) (523,666)  
Net foreign exchange gains/(losses) (27,603) 363,724 247,558
Movement in inventory provision  
General and administrative expenses (4,091,910) (3,786,910) (3,360,301)
Research and development expenses
Selling and marketing expenses
Operating profit/(loss) (4,667,184) (3,946,852) (3,112,743)
Finance income 327,756 116,323 21,785
Finance costs (7,576) (9,652) (6,184)
Share of loss from associates (1,456,019) (324,340)  
Income tax expense  
Profit/(loss) for the year (5,813,028) (4,164,521) (3,097,142)
Assets      
Segment assets 11,936,503 19,511,148 22,909,414
Total assets 11,936,503 19,511,148 22,909,414
Liabilities      
Segment liabilities 2,029,983 1,560,804 1,521,219
Total liabilities $ 2,029,983 $ 1,560,804 $ 1,521,219